a public good project by the
Synthesis
Company
of California

© 2026

Claus Garbe | doi.page

0 works0 citations0 h-index

Claus Garbe

Publications by Year

Research Areas

Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers

Most-Cited Works

→ Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation(2011)7,653 cited
→ Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma(2011)4,451 cited
→ Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma(2012)2,130 cited
→ Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma(2014)2,015 cited
→ Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma(2014)1,843 cited
→ Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial(2015)1,372 cited
→ Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

(2012)

1,342 cited

→ Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma(2019)1,338 cited

→ Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial(2018)1,007 cited

→ Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial(2016)994 cited